The medicine digoxin is already in use for treating heart disease patients suffering from congestive heart failure & irregular cardiac rhythms. Presently, scientists state that it may well aid in combating prostate cancer by halting development of the disease.

Researchers at the JHU, Baltimore uncovered that digoxin reduced prostate cancer risk by twenty-four percent in the 47000 males who underwent testing.

However, they caution that these outcomes are not proving that digoxin (with associated side-effects like feeling nauseous, headache & man breasts forming) thwarts the disease.

Prof. E. Platz stated that their study team came to the realization that merging their lab & epidemiological strategies can lower the chances that outcomes on the candidate medications may be because of cancer. She added that including the epidemiological trial to the medication screen step offered an evaluation of the medication’s likely activity in individuals.

Professor Platz emphasized that there’s zilch indication that digoxin, which could be having grave side-effects inclusive of cardiac abnormalities, must be deployed as a pre-emptive therapy for prostate cancer. She adds that digoxin isn’t a medication that one would be giving to individuals in good health.

Researchers started to screen over 3000 compounds that have existent approval for medicinal usage to check whether any hampered the development of prostate cancer cells. Digoxin surfaced as a forerunner surpassing thirty-eight potential contenders.

An epidemiologist group then probed for proof of the medication fighting prostate cancer in a patients health trial.

The scientists examined medical records involving 47000 males in the age band of forty to seventy-five years of age, whose continual monitoring were done since 1986 onwards till 3 decades later.

In the set, about five thousand novel prostate cancer cases were cited. Males who were regular digoxin takers constituted 2% of the group. They had a twenty-four percent lesser likelihood of developing prostate cancer as compared to those not using the medicine.

Deploying digoxin for over a decade slashed their prostate cancer risk by fifty percent. Additional work would ascertain the method of the drug’s effect & check if the medication or several similar to it must be evaluated as therapies for prostate cancer.

The drug has been observed to alter biologic paths for K, Na in cardiac cells and researchers deem that it might be acting on analogous paths in prostate cancer cells.

Monthly Low-dose Aspirin lowers Pancreatic Cancer Risk

Aspirin could considerably lower the likelihood of getting the highly lethal form of cancer, pancreatic cancer, a trial has noted.

Intake of the pain-allayer on one time per month was observed to lower pancreatic cancer risk by twenty-six percent.

More frequent usage of low-dosage aspirin for preventing heart disease appeared to make individuals thirty-five percent lesser prone to having the condition.

Scientists did a comparison of over nine hundred sufferers of pancreatic cancer in their mid-fifties onwards with 1224 people in good health. Every patient in the trial was questioned regarding his/ her usage of aspirin, other inflammation-combating medications & the pain-allayer acetaminophen. The trial revealed zero gains from any of the medications aside from aspirin.

Main scientist Doctor Xiang-Lin Tan, of Mayo Clinic, United States stated that the outcomes aren’t meaning to indicate that all must commence once-a-month intake of aspirin for reducing their pancreatic cancer risk. People must be discussing aspirin usage with their doctors since it does carry a number of side-effects.

Additional studies are necessary prior to finally concluding anything, Doctor Tan emphasized.

Presentation of the trial outcomes was done lately at the yearly AACR conference held in Florida.

Yearly, 7680 individuals in the United Kingdom are identified with pancreatic cancer & an analogous number of individuals dying due to the condition. Pancreatic cancer has pitiable outlook, with merely 3% of those ailing manage to survive past 5 years. The span of time amid being diagnosed & mortality is classically just 6 months.

A research group headed by Prof. Ingrid Herr, HOD, Molecular Oncosurgery, Heidelberg Univ. Hospital in collaboration with the German Cancer Research Center, evaluated the novel substance in rodent and pancreatic cancer cells. It hampered resistance-exhibiting cancer stem cells and was additionally effectual when merged with sulforaphene, an organic constituent present in broccoli.

Annually, pancreatic cancer develops in around 12900 Germans and is often spotted quite later on thus leading to fewer individuals surviving the analysis more than a year’s time. Particularly, early harbinger cancer cells called as cancer stem cells are accountable for uninhibited cancer development, metastasis to several organs and reappearance briefly post-surgical procedure.

Sorafenib is additionally effectual in Pancreas Cancer

The study outcomes available online in ‘Cancer Research’ medical journal follow several tests being conducted on tumor cells and rodent models. Study investigators found that sorafenib restrained characteristic traits of tumor stem cells from pancreas tumors and vastly lowered cancer development. But, this outcome was found to last merely for a brief period and subsequent to 4 weeks time; new-fangled clusters of tumor stem cells developed which had become resistant to additional therapy involving sorafenib.

One of the study researchers, Vanessa Rausch from Heidelberg Univ. Hospital expounded that this non-reactivity to sorafenib therapies is possibly linked to a particular metabolic path, known as the NF-kB path way which the drug Sorafenib triggers.

Broccoli – Potent fortifier of Sorafenib’s Effects in treating Pancreas Cancer

There are several innately present substances which accurately obstruct the unwanted NF-KB path way and consequently make the hazardous cells susceptible – veggies belonging to the Brassicacaeae or Cruciferae family like broccoli, mustard greens, varied cabbage types, brussel sprouts and kale have an elevated presence of sulforaphene, a cancer-tackling compound. The trials showed that sulforaphene averted triggering of the NF-kB path by sorafenib. Combo therapy strengthens the outcome of sorafenib while not being causal to any further side-effects. Aggressive potential of cancerous cells was thwarted and there was total blockage of the cancer cells metastasizing in cell culture trials.

Prof. Dr. Herr indicated that nutrition could be a suitable strategy for breaking treatment non-reactivity among cancerous stem cells and hence make cancer therapy vastly effectual.

The test employs an antibody that functions as a heat-detecting projectile that homes in and attaches to cells which bear PAM4 protein which is found vastly in pancreatic cancer cases.

The researchers stated that this protein is pancreatic cancer-specific and is atypically present in healthy tissues or in other types of cancers.

Vitally, PAM4 is hardly ever identified in pancreatitis – an ailment wherein there is pancreatic inflammation which is originally mostly tricky in distinguishing from pancreatic cancer. The antibody additionally shows potential for treatment of cancer by functioning as a carter for radiation or medicines which could be helpful in targeting and killing pancreatic cancer-ridden cells.

Pancreatic cancer is a killer disease and holds the fourth position for the prevalent reasons behind cancer fatalities in both genders as they are diagnosed in stages when cancer has metastasized all through the body.

The objective of this study was that this novel test would offer a means of detecting the disease in its preliminary stages as survival chances leap twenty percent when spotted early on.

Presently, just seven percent of pancreatic cancer cases have been diagnosed in the preliminary staging prior to cancer having metastasized.

The scientists initially did a trial of the test on blood samples drawn from about three hundred individuals, all of whom had different kinds of cancers like pancreatic cancer, breast, lung and few of them were in good health.

The blood test revealed affirmative outcomes in seventy-seven percent of the patients having pancreatic cancer and merely five percent of patients that had other kinds of cancer. Hence, the researchers were able to infer that in case the test gave an affirmative outcome then there were greater chances that a person was having pancreatic cancer.

During the new-fangled study, the scientists assessed the PAM4 protein test among sixty-eight individuals that had undergone surgery for treating pancreatic cancer and nineteen individuals in good health.

The test accurately diagnosed quite preliminary staging pancreatic cancers in sixty-two percent of the cases which were still restricted to the pancreas, eighty-six percent of cases which had metastasized solely to the adjoining tissues and ninety-one percent of late-staged cancers which had metastasized more all through the body.

By and large, the test accurately diagnosed eighty-one percent of all the pancreatic cancer cases.

Pancreatic Cancer Screening

In case these findings could be corroborated in a wider populace of individuals then the researchers envisage that the test could be employed for screening individuals at elevated risk of developing pancreatic cancer. Those in high-risk bracket include those with long-standing diabetes, those suffering from unceasing pancreatitis and individuals having a past of tobacco or alcohol usage, family history or heritable aspects.

In case pancreatic cancer is suspected, then the test could be useful in distinguishing in-between varying cancer forms and normal tissues. The test could additionally be employed for monitoring patients who have been through treatments for signs of relapse.

The researchers forecast that this test would be obtainable in 2 to 3 years.

The researchers in a separately performed study on twenty-one individuals having advanced staging pancreatic cancer an injection of antibody affixed-radioactive isotopes was administered. The objective being that no sooner did the antibody home in on the cancerous cells there would be release of radiation obliterating the tumor cells while normal tissues would be spared. During the study there was tissue shrinkage in among twenty-three percent patients whereas in additionally forty-five percent of the cases there was stoppage of tumor growth.

Pancreas is an elongate-shaped, nearly 6 inches long, situated in the upper region of the abdomen performing two vital tasks:

• Production of digestive enzymes that are proteins aiding in assimilating food into the small intestine. Cells that carry out this task constitute the exocrine pancreas.
• The second significant task is hormone production that gets released into the blood. These cells constitute the endocrine pancreas.

Endocrine Pancreas

The endocrine pancreas comprise of particular cells, known as the islets of Langerhans that secrete hormones. The most vital hormone being secreted is insulin that aids in managing blood glucose levels. Cancers that originate in the islet cells are known as islet cell tumors or pancreatic neuroendocrine tumors. Such tumors are atypical and could secrete hormones that cause major fluctuations in the blood glucose levels or lead to signs like pain and discomfort in the stomach and acute diarrhea.

Exocrine Pancreas

The exocrine pancreas comprise of ducts and acini that are tiny compartments located at the end of the ducts. The cells that line the ducts are most prone to developing cancer, known as ductal adenocarcinomas – the most prevalent form of pancreatic cancer.

Pancreatic cancer is mostly referred to as a tacit disease as it characteristically is asymptomatic in its early stages. The cancer could metastasize, spreading for a while till the symptoms start becoming evident. The early signs are so unclear that often they are primarily overlooked, due to which pancreatic cancer detection is tough in the early stages.

In several situations, the cancer has proliferated beyond the pancreas by the time it is spotted. When symptoms do start appearing, their kind and extent is dependent on where the tumor is located and how big is the tumor in size.

Prevalent signs might comprise of:

Jaundice

In case there is blockage in the bile duct caused due to the tumor, there is major hindrance in the flow of bile into the intestines leading to jaundice that makes the affected person’s skin and the white areas of the eyes turn yellowish. Jaundice causes the urine to turn a darker shade and the faeces could turn whitish like clay in colour.

Pain and Discomfort

When the cancer metastasizes, pain mostly is sensed in the upper section of the abdominal region and the back. The pain would often intensify subsequent to consuming anything or while lying down.

Reduction in weight

Pancreatic cancer could additionally lead to weight reduction. This mostly occurs because of the insufficient calorific ingestion due to the nauseous feeling, puking and depleted appetite.

Digestive Disorders

Indigestion could be the consequence of the cancer hindering the free passage of the pancreatic juices into the intestines that assist in breaking down the dietetic fats, proteins and carbohydrates inside the body. Stools could appear unusually pallid, bulky or slippery, appear afloat in the toilet, or emit a particular fetid stench.

Risk Factors

Though the reasons leading to pancreatic cancer are still ambiguous, some risk factors have been detected that raise an individual’s likelihood of developing pancreatic cancer. These comprise of:

Smoking

Smoking is known to raise the risk of developing pancreatic cancer by two to three folds as compared to non-smokers.

Age

The risk of developing pancreatic cancer is directly proportional to age. Those individuals past sixty years or more have been widely identified with the disease.

Race

Certain races like Afro-Americans have been observed to have more cases of pancreatic cancer as compared to Asian, Hispanic and white races.

Chronic Pancreatitis

Those who have previously ailed from chronic pancreatitis are more likely to develop pancreatic cancer.

Diabetes

Pancreatic cancer is more often known to affect some diabetics.  Diabetes might additionally be a complication or a preliminary symptom of pancreatic cancer.

Dietetic Intake

A regular dietetic intake of fat-rich foods, particularly processed red meats, might raise the likelihood of developing the disease.

Being Overweight

Those with weight issues like being obese or overweight have greater risk of developing pancreatic cancer.

Genetics

Though majority of the pancreatic cancer cases are not genetic in nature, hereditary conditions could raise the likelihood of developing pancreatic cancer.

Nearly 5-10% cases of pancreatic cancer cases are deemed heritable or associated to a particular genetic mutation. Pancreatic cancer is believed to be present in those families that have 2 or more first-degree blood relatives – like parents, brothers/sisters or kids – have the disease. This is at times known as familial pancreatic cancer or FPC. In case an individual is having a first-degree relative having pancreatic cancer, then it majorly raises that person’s risk in comparison to the average individual.

An elevated risk has additionally been linked with several genetic syndromes inclusive of genetic breast, ovarian and colon cancer and a grave form of skin cancer known as FAMMM or familial atypical multiple mole syndrome.